| Sep 1, 2018 | VelosBio | $58.0M Series A | Arix Bioscience, Sofinnova Ventures | Tom Hulme, MPM Capital, Soffinova Partners, Chiesi Ventures, Decheng Capital, Takeda Ventures |
| Jul 25, 2017 | Kezar Life Sciences | $50.0M Series B | Bihua Chen, Morningside | AJU IB Investment, Bay City Capital, Cowen Healthcare Investments, EcoR1 Capital, Omega Funds, Qiming Venture Partners |
| Oct 1, 2016 | Evidation Health | $3.0M Series B | B Capital Group | Asset Management Ventures, Fresco Capital, GE Ventures |
| Aug 1, 2016 | Rotation Medical | $12.0M Series B | — | Amzak Health Investors, Avoro Ventures, Canaan Partners, EQT Life Sciences, Flagship Pioneering, Mott Family Capital, New Enterprise Associates, OrbiMed, Westlake Village BioPartners, Jason Henrichs, LSP |
| Mar 1, 2015 | Thrasos | $21.0M Series D | BDC Venture Capital, Jens Eckstein | Amorchem, Apollo Health Ventures, Advanced Technology Ventures, Lumira Ventures, MP Healthcare Venture Management, SW Co. |
| Jan 1, 2015 | CoLucid Pharmaceuticals | $37.0M Series C | Dr. Luc Marengere | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures, Auriga Partners, Care Capital, Martin Edwards, Pearl Street Venture Funds, Triathlon Medical Ventures |
| Jul 1, 2014 | Rotation Medical | $27.0M Series B | New Enterprise Associates, Rudy De Keyser | Amzak Health Investors, Avoro Ventures, Canaan Partners, EQT Life Sciences, Flagship Pioneering, Mott Family Capital, OrbiMed, Westlake Village BioPartners, Jason Henrichs, Scott Weiner |
| Nov 1, 2013 | Envisia Therapeutics | $25.0M Series A | — | Canaan Partners, Canaan Partners, Morningside, New Enterprise Associates, Wakefield Group |
| May 1, 2013 | Lumena Pharmaceuticals | $23.0M Series A | — | RiverVest, Robert Alexander, David R. Savello, John McKearn |
| Oct 25, 2012 | Thrasos | $35.0M Other Equity | Jens Eckstein | Advanced Technology Ventures, GlaxoSmithKline, Lumira Ventures, MP Healthcare Venture Management, SW Co. |
| Sep 1, 2012 | IlluminOss Medical | $28.0M Series C | Fouad Azzam, Ph.D., Daniel Omstead | EQT Life Sciences, Enrico Petrillo MD, Foundation Medical Partners, Mieza Capital, New Leaf Venture Partners, Slater Technology Fund, Rajeev Dadoo |
| Aug 27, 2012 | CardioDx | $58.0M Other Equity | — | Artiman Ventures, Asset Management Group, Bright Capital, DAG Ventures, GE Capital, Intel Capital, J.P. Morgan, Kleiner Perkins, Longitude Capital, Mohr Davidow Ventures, RU-COM, Temasek, TPG Biotech |
| Feb 20, 2012 | Lumena Pharmaceuticals | $2.5M Other Equity | Pappas Ventures, RiverVest Venture Partners | — |
| Dec 9, 2011 | CeNeRx BioPharma | $4.8M Other Equity | — | L Capital Partners, Omega Funds, Perseus-Soros Biopharmaceutical Fund |
| Aug 30, 2011 | CoLucid Pharmaceuticals | $7.5M Other Equity | — | Care Capital, Domain Associates, Art Pappas, Pearl Street Venture Funds, Triathlon Medical Ventures |
| Jun 21, 2011 | TESARO, Inc. | $101.0M Series B | Beth Seidenberg | Deerfield Management, Arnie Oronsky, Leerink Partners, Paul Walker, Oracle Partners, T. Rowe Price Associates |
| Jun 1, 2011 | Ultragenyx Pharmaceutical | $45.0M Series A | Ben Auspitz, Eran Nadav | Earlybird Venture Capital, F-Prime Capital Partners, HealthCap |
| Jun 1, 2011 | Milestone Pharmaceuticals | $13.0M Series A | Ela Borenstein, Go Capital, Scott Weiner | Mission BioCapital, Fonds Bio-Innovation, Inovia Capital |
| Feb 1, 2011 | Chimerix | $45.0M Series F | James Niedel | Canaan Partners, Endeavor Venture Funds, Frazier Healthcare Partners, InterWest, Robert Garland, Polaris Partners, Alta Partners, Asset Management, Canaan Partners, Morningside, Art Pappas, Sanderling Ventures |
| Aug 15, 2010 | Syndax Pharmaceuticals | $6.0M Other Equity | — | Avalon Ventures, Domain Associates, Forward Ventures, MC Life Science Ventures, MPM Capital |
| Aug 13, 2010 | CeNeRx BioPharma | $13.0M Series C | — | L Capital Partners, Perseus-Soros Biopharmaceutical Fund |
| Apr 20, 2010 | Liquidia Technologies | $25.0M Series C | — | Stephen Bloch, Firelake Capital, Isaac Cheng, New Enterprise Associates, PPD |
| Dec 1, 2009 | Afferent Pharmaceuticals | $23.0M Series A | Pappas Ventures, Third Rock Ventures | Access Biotechnology, Canaan Partners, Domain Associates, New Leaf Venture Partners |
| Oct 17, 2008 | CeNeRx BioPharma | $15.0M Other Equity | — | Aisling Capital, L Capital Partners |
